In this study, we demonstrate that CD9 is highly expressed in CD34+CD38− AML LSCs and shows extremely low or no expression in normal HSCs, which indicates CD9 to be as a promising therapeutic target in AML. This evidence concerns the gene CD34 and acute myeloid leukemia.